United Therapeutics (UTHR) awards 760 RSUs to board director Judy D. Olian

Rhea-AI Filing Summary

Olian Judy D. reported acquisition or exercise transactions in this Form 4 filing.

United Therapeutics Corporation director Judy D. Olian received an annual non-employee director equity award of 760 restricted stock units (RSUs) on July 22, 2026. Each RSU entitles her to one share of common stock after vesting, with full vesting on the earlier of the one-year anniversary of grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following this award, she holds 760 RSUs and 5,555 shares of common stock directly. The RSUs have no expiration date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Olian Judy D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit F1, F2, F3, F4	760	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Unit — 760 shares (Direct); Common Stock — 5,555 shares (Direct)

Footnotes (4)

1. F1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
2. F2. Annual non-employee director award.
3. F3. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
4. F4. Not applicable as restricted stock units do not have an expiration date.

Key Figures

RSUs granted: 760 restricted stock units Conversion ratio: 1 share of common stock per RSU Common shares held after transaction: 5,555 shares +2 more

5 metrics

RSUs granted 760 restricted stock units Annual non-employee director award on 2026-07-22

Conversion ratio 1 share of common stock per RSU Each restricted stock unit represents the right to receive one share after vesting

Common shares held after transaction 5,555 shares Direct ownership of United Therapeutics common stock following the reported award

Anticipated Annual Meeting / vesting reference date June 25, 2027 Awards become fully vested by the earlier of one year after grant or the next Annual Meeting; June 25, 2027 is the anticipated meeting date

Exercise/Conversion price $0.0000 per share Conversion or exercise price for the restricted stock units

Key Terms

Restricted Stock Unit, Annual non-employee director award, Annual Meeting of Shareholders

3 terms

Restricted Stock Unit financial

"Each restricted stock unit represents the right to receive, following vesting, one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Annual non-employee director award financial

"Annual non-employee director award."

Annual Meeting of Shareholders financial

"the date of the next Annual Meeting of Shareholders following the grant date"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/23/2026 - 04:44 PM Accepted by SEC EDGAR 07/23/2026 - 04:44 PM Learn about SEC filing dates

FAQ

What equity award did United Therapeutics (UTHR) grant to director Judy D. Olian?

United Therapeutics granted director Judy D. Olian 760 restricted stock units (RSUs) as an annual non-employee director award on July 22, 2026. Each RSU converts into one share of common stock upon vesting, adding to her existing direct equity stake in the company.

How many United Therapeutics (UTHR) shares does Judy D. Olian hold after this Form 4 filing?

After the reported award, Judy D. Olian directly holds 5,555 shares of common stock in United Therapeutics and 760 RSUs. Each RSU represents the right to receive one additional common share upon vesting, increasing her potential future ownership.

When will Judy D. Olian’s United Therapeutics (UTHR) RSUs vest?

The 760 RSUs for Judy D. Olian become fully vested on the earlier of one year after the grant date or the date of the next Annual Meeting of Shareholders. June 25, 2027 is identified as the anticipated date of that Annual Meeting.

Do Judy D. Olian’s United Therapeutics (UTHR) restricted stock units have an expiration date?

The filing states that the restricted stock units do not have an expiration date. They represent a right to receive United Therapeutics common stock after vesting, rather than options that expire if not exercised by a certain deadline.

What type of insider transaction did United Therapeutics (UTHR) report for Judy D. Olian?

The company reported an acquisition via grant/award of 760 restricted stock units to Judy D. Olian, coded as a grant rather than a market purchase or sale. This reflects routine board compensation, not an open-market trading transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Olian Judy D.

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								5,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0.00(1)	07/22/2026		A		760(2)		06/25/2027(3)	(4)	Common Stock	760	$0.00	760	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

2. Annual non-employee director award.

3. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

4. Not applicable as restricted stock units do not have an expiration date.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)